第65回日本神経学会学術大会/AOCN2024

第65回日本神経学会学術大会/AOCN2024

2024年5月29日〜6月1日東京国際フォーラム
日本神経学会学術大会
第65回日本神経学会学術大会/AOCN2024

第65回日本神経学会学術大会/AOCN2024

2024年5月29日〜6月1日東京国際フォーラム

[HT-02-3]ARISE study: A Global Phase 2 trial of Tilavonemab in progressive supranuclear palsy

Nahome T. Fisseha(Japan Development, AbbVie GK)
photo
Nahome Fisseha is Japan Asset Strategy Leader & Chief of Staff at AbbVie. He leads multidisciplinary teams that develop and commercialize pharmaceutical products across neuroscience, immunology, and virology therapeutic areas. Previously, Nahome served as global Scientific Director of Neuroscience Clinical Development at AbbVie working on early-to-late stage clinical programs including, in Alzheimer's disease. Parkinson's disease and progressive supranuclear palsy. He also served as precision medicine lead for neurodegenerative disorders, overseeing teams accountable for development of translational strategy and the delivery of biofluid, imaging and digital biomarkers. Nahome attended the University of Illinois at Chicago where he received his Doctor of Pharmacy degree and Drake University where he received his bachelor’s degree in Biochemistry, Cell and Molecular Biology.

閲覧にはパスワードが必要です

抄録パスワード認証
第65回日本神経学会学術大会プログラム・抄録集の19ページに記載しています。